Danaher continues to charge exorbitant prices for lifesaving medical tests despite urgent demands for price reductions by several Ministries of Health
Geneva, 17 June 2024 – In September 2023, the US corporation Danaher, which owns diagnostics maker Cepheid, announced a price reduction of the primary GeneXpert test used to diagnose tuberculosis (TB), from US$9.98 to $7.97,